[
  {
    "ts": "2025-10-17T22:13:01+00:00",
    "headline": "How a Texas Court Ruling on Medicare Advantage Ratings Has Reshaped Humana’s (HUM) Investment Story",
    "summary": "Earlier this week, a Texas judge ruled against Humana in a legal challenge, upholding government-imposed downgrades to Medicare Advantage quality star ratings and confirming cuts to related bonus payments, which could impact billions of dollars in revenue for the company. This court decision introduces significant uncertainty for Humana’s core Medicare Advantage business, as quality ratings are a key factor in determining government reimbursement rates. We'll examine how this legal setback...",
    "url": "https://finance.yahoo.com/news/texas-court-ruling-medicare-advantage-221301195.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "ff7d2a81-e2b8-3f07-9644-6393427f68dc",
      "content": {
        "id": "ff7d2a81-e2b8-3f07-9644-6393427f68dc",
        "contentType": "STORY",
        "title": "How a Texas Court Ruling on Medicare Advantage Ratings Has Reshaped Humana’s (HUM) Investment Story",
        "description": "",
        "summary": "Earlier this week, a Texas judge ruled against Humana in a legal challenge, upholding government-imposed downgrades to Medicare Advantage quality star ratings and confirming cuts to related bonus payments, which could impact billions of dollars in revenue for the company. This court decision introduces significant uncertainty for Humana’s core Medicare Advantage business, as quality ratings are a key factor in determining government reimbursement rates. We'll examine how this legal setback...",
        "pubDate": "2025-10-17T22:13:01Z",
        "displayTime": "2025-10-17T22:13:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f6ed28f0d41f879bd5a978786002c2db",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Hmp2bSpG9df53vmcWkUJ8g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f6ed28f0d41f879bd5a978786002c2db.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KUEpq9U8lIeW2zfadEuUSw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f6ed28f0d41f879bd5a978786002c2db.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/texas-court-ruling-medicare-advantage-221301195.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/texas-court-ruling-medicare-advantage-221301195.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HUM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-17T19:14:05+00:00",
    "headline": "Medicare Part D plans: Expert reveals that 95% of beneficiaries are overspending on prescriptions",
    "summary": "Nearly all 55 million Medicare users overpay for prescriptions. Expert Katy Votava explains how to compare Part D plans and save thousands.",
    "url": "https://finance.yahoo.com/news/medicare-part-d-plans-expert-reveals-that-95-of-beneficiaries-are-overspending-on-prescriptions-191405414.html",
    "source": "Yahoo Finance",
    "provider": "yfinance",
    "raw": {
      "id": "6587b1c2-ca90-4518-a3e4-7a85645351e8",
      "content": {
        "id": "6587b1c2-ca90-4518-a3e4-7a85645351e8",
        "contentType": "STORY",
        "title": "Medicare Part D plans: Expert reveals that 95% of beneficiaries are overspending on prescriptions",
        "description": "",
        "summary": "Nearly all 55 million Medicare users overpay for prescriptions. Expert Katy Votava explains how to compare Part D plans and save thousands.",
        "pubDate": "2025-10-17T19:14:05Z",
        "displayTime": "2025-10-17T19:14:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-10/6cf54060-aab5-11f0-aff9-0cb189e1520e",
          "originalWidth": 5000,
          "originalHeight": 3333,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vPXx8dOp4vdP7EGmwaA_9Q--~B/aD0zMzMzO3c9NTAwMDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-10/6cf54060-aab5-11f0-aff9-0cb189e1520e.cf.webp",
              "width": 5000,
              "height": 3333,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/osWg71lr_wwPxhsuOuO6Xw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-10/6cf54060-aab5-11f0-aff9-0cb189e1520e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance",
          "url": "http://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/medicare-part-d-plans-expert-reveals-that-95-of-beneficiaries-are-overspending-on-prescriptions-191405414.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/medicare-part-d-plans-expert-reveals-that-95-of-beneficiaries-are-overspending-on-prescriptions-191405414.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "UNH"
            },
            {
              "symbol": "CVS"
            },
            {
              "symbol": "CNC"
            },
            {
              "symbol": "HUM"
            },
            {
              "symbol": "CI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-17T13:50:02+00:00",
    "headline": "Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finance.yahoo.com/news/why-1-momentum-stock-could-135002308.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "b814eacb-0964-372e-b35a-443b90c0a898",
      "content": {
        "id": "b814eacb-0964-372e-b35a-443b90c0a898",
        "contentType": "STORY",
        "title": "Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio",
        "description": "",
        "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
        "pubDate": "2025-10-17T13:50:02Z",
        "displayTime": "2025-10-17T13:50:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f",
          "originalWidth": 900,
          "originalHeight": 601,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EmhBrL1RMEs5kGBSUQzx5g--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f.cf.webp",
              "width": 900,
              "height": 601,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CMWRvhn58nUVOwpQjtvr2Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-1-momentum-stock-could-135002308.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-1-momentum-stock-could-135002308.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HUM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-17T13:40:03+00:00",
    "headline": "Are Investors Undervaluing Humana (HUM) Right Now?",
    "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
    "url": "https://finance.yahoo.com/news/investors-undervaluing-humana-hum-now-134003060.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "d916abd2-f0c6-3b5b-b6f4-d59dafe61f94",
      "content": {
        "id": "d916abd2-f0c6-3b5b-b6f4-d59dafe61f94",
        "contentType": "STORY",
        "title": "Are Investors Undervaluing Humana (HUM) Right Now?",
        "description": "",
        "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
        "pubDate": "2025-10-17T13:40:03Z",
        "displayTime": "2025-10-17T13:40:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94",
          "originalWidth": 900,
          "originalHeight": 588,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5gRNxwBpnI6i3Dv1dI7wfg--~B/aD01ODg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94.cf.webp",
              "width": 900,
              "height": 588,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3D4iv84vYyo09.dnUK_wsg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/investors-undervaluing-humana-hum-now-134003060.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/investors-undervaluing-humana-hum-now-134003060.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HUM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-17T13:40:02+00:00",
    "headline": "Is Beam Therapeutics (BEAM) Stock Outpacing Its Medical Peers This Year?",
    "summary": "Here is how Beam Therapeutics Inc. (BEAM) and Humana (HUM) have performed compared to their sector so far this year.",
    "url": "https://finance.yahoo.com/news/beam-therapeutics-beam-stock-outpacing-134002975.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "31e59c94-b824-32b4-8787-ddfac5797533",
      "content": {
        "id": "31e59c94-b824-32b4-8787-ddfac5797533",
        "contentType": "STORY",
        "title": "Is Beam Therapeutics (BEAM) Stock Outpacing Its Medical Peers This Year?",
        "description": "",
        "summary": "Here is how Beam Therapeutics Inc. (BEAM) and Humana (HUM) have performed compared to their sector so far this year.",
        "pubDate": "2025-10-17T13:40:02Z",
        "displayTime": "2025-10-17T13:40:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83",
          "originalWidth": 900,
          "originalHeight": 633,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y5JgUaFZFuBLe5dh5H4ng--~B/aD02MzM7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83.cf.webp",
              "width": 900,
              "height": 633,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IGtpvtZ0OkzJMDD0I3exBg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/beam-therapeutics-beam-stock-outpacing-134002975.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/beam-therapeutics-beam-stock-outpacing-134002975.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HUM"
            },
            {
              "symbol": "BEAM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]